Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Jasvinder K. Atwal"'
Autor:
Vidya Ramakrishnan, Christina Friedrich, Colleen Witt, Robert Sheehan, Meghan Pryor, Jasvinder K. Atwal, Kristin Wildsmith, Katherine Kudrycki, Seung‐Hye Lee, Norman Mazer, Carsten Hofmann, Reina N. Fuji, Jin Y. Jin, Saroja Ramanujan, Michael Dolton, Angelica Quartino
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 1, Pp 62-73 (2023)
Abstract Despite considerable investment into potential therapeutic approaches for Alzheimer's disease (AD), currently approved treatment options are limited. Predictive modeling using quantitative systems pharmacology (QSP) can be used to guide the
Externí odkaz:
https://doaj.org/article/6c9f800424f0462f8528114142c69f0a
Autor:
William J. Meilandt, Janice A. Maloney, Jose Imperio, Guita Lalehzadeh, Tim Earr, Susan Crowell, Travis W. Bainbridge, Yanmei Lu, James A. Ernst, Reina N. Fuji, Jasvinder K. Atwal
Publikováno v:
Alzheimer’s Research & Therapy, Vol 11, Iss 1, Pp 1-14 (2019)
Abstract Background Accumulation of amyloid β (Aβ) in the brain is proposed as a cause of Alzheimer’s disease (AD), with Aβ oligomers hypothesized to be the primary mediators of neurotoxicity. Crenezumab is a humanized immunoglobulin G4 monoclon
Externí odkaz:
https://doaj.org/article/bd282779d343414aa689f312c255a80f
Autor:
Vidya Ramakrishnan, Christina Friedrich, Colleen Witt, Robert Sheehan, Meghan Pryor, Jasvinder K. Atwal, Kristin Wildsmith, Katherine Kudrycki, Seung‐Hye Lee, Norman Mazer, Carsten Hofmann, Reina N. Fuji, Jin Y. Jin, Saroja Ramanujan, Michael Dolton, Angelica Quartino
Publikováno v:
CPT: pharmacometricssystems pharmacologyREFERENCES.
Despite considerable investment into potential therapeutic approaches for Alzheimer's disease (AD), currently approved treatment options are limited. Predictive modeling using quantitative systems pharmacology (QSP) can be used to guide the design of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::deef4ef903540f5e9867ffd67b1e04a3
https://pubmed.ncbi.nlm.nih.gov/36281062
https://pubmed.ncbi.nlm.nih.gov/36281062
Autor:
James A. Ernst, Tim Earr, Guita Lalehzadeh, Travis W. Bainbridge, Susan Crowell, William J. Meilandt, Jose Imperio, Reina N. Fuji, Yanmei Lu, Janice A. Maloney, Jasvinder K. Atwal
Publikováno v:
Alzheimer’s Research & Therapy, Vol 11, Iss 1, Pp 1-14 (2019)
Alzheimer's Research & Therapy
Alzheimer's Research & Therapy
Background Accumulation of amyloid β (Aβ) in the brain is proposed as a cause of Alzheimer’s disease (AD), with Aβ oligomers hypothesized to be the primary mediators of neurotoxicity. Crenezumab is a humanized immunoglobulin G4 monoclonal antibo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd56a26eaed0bb2a4cfdf03b4b10e492
https://doaj.org/article/bd282779d343414aa689f312c255a80f
https://doaj.org/article/bd282779d343414aa689f312c255a80f
Autor:
Gautham K. Rao, Stephen P. Schauer, Edmond Teng, Joseph Bravo, Reina N. Fuji, Andrea Pfeifer, Yong Ying, Kimberly Scearce-Levie, Jessica Couch, Hilda Solanoy, Paul T. Manser, Andreas Muhs, Han Lin, Daniela Bumbaca Yadav, Oded Foreman, Dongping He, James A. Ernst, Flavia Brunstein, Hai Ngu, Michael C. M. Kwok, Maria Pihlgren, Oskar Adolfsson, Mira Blendstrup, William B. Smith, Priya Chandra, Akash Datwani, Michael Keeley, Danielle DiCara, Robert Brendza, Yanmei Lu, Julien Lafrance-Vanasse, Corinne Foo-Atkins, Jasvinder K. Atwal, Isidro Hötzel, Seung-Hye Lee, Kristin R. Wildsmith, Ruby Chan, Helen Booler, Rich Erickson, Barthélemy Demeule, Geoffrey A. Kerchner, Wilman Luk, Gai Ayalon
Publikováno v:
Science Translational Medicine. 13
Tau has become an attractive alternative target for passive immunotherapy efforts for Alzheimer's disease (AD). The anatomical distribution and extent of tau pathology correlate with disease course and severity better than other disease markers to da
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c8226f0212aa58c81fd5ec5abd2b2f7
https://doi.org/10.1126/scitranslmed.abb2639
https://doi.org/10.1126/scitranslmed.abb2639
Autor:
Karen Hayes, Reina N. Fuji, Lisa L. Shafer, Saileta Prabhu, William J. Meilandt, Keith R. Hildebrand, Ryan J. Watts, Thomas Keene, Jessica Couch, Blair Wilson, Jasvinder K. Atwal, Janice A. Maloney, Ann L. Daugherty, Kapil Gadkar, Kimberly Scearce-Levie, Kristin R. Wildsmith, Yanmei Lu, Andrew Kosky, Marisa Goo, Robert C. Switzer, Kun Peng, Eric Adams, Deepak R. Thakker, Pamela Chan, Deanna S. Lane, Lisa Jungbauer Nikolas, Hilda Solanoy, Daniela Bumbaca Yadav
Publikováno v:
British Journal of Pharmacology. 174:4173-4185
Background and Purpose The potential for therapeutic antibody treatment of neurological diseases is limited by poor penetration across the blood–brain barrier. I.c.v. delivery is a promising route to the brain; however, it is unclear how efficientl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4e0802c2e55ddcc52775ac9687bc8dd4
https://doi.org/10.1111/bph.14021
https://doi.org/10.1111/bph.14021
Autor:
Tony Sun, Gregory Z. Ferl, Saroja Ramanujan, Angelica Quartino, Reina N. Fuji, Jasvinder K. Atwal
Publikováno v:
Current Alzheimer research. 17(4)
Background: Anti-amyloid-β (Aβ) monoclonal antibodies (mAbs) are currently in development for treating Alzheimer’s disease. Objectives: To address the complexity of Aβ target engagement profiles, improve the understanding of crenezumab Pharmacok
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a39353f031415c02ff4d730ba55cf77c
https://pubmed.ncbi.nlm.nih.gov/32116192
https://pubmed.ncbi.nlm.nih.gov/32116192
Autor:
Ryan J. Watts, Oded Foreman, Maria Pihlgren, Ruby Chan, Valerie Gafner, Karpagam Srinivasan, David V. Hansen, Hai Ngu, Oskar Adolfsson, Jasvinder K. Atwal, Yanmei Lu, Robert Brendza, Andreas Muhs, Han Lin, Gai Ayalon, Seung-Hye Lee, Andrea Pfeifer, Kimberly Scearce-Levie, James A. Ernst, Daniela Bumbaca, Hilda Solanoy, Danielle DiCara, Isidro Hötzel, Claire E. Le Pichon
Publikováno v:
Cell Reports, Vol 16, Iss 6, Pp 1690-1700 (2016)
SummaryThe spread of tau pathology correlates with cognitive decline in Alzheimer’s disease. In vitro, tau antibodies can block cell-to-cell tau spreading. Although mechanisms of anti-tau function in vivo are unknown, effector function might promot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4556d04844f372b30085ce4e4ff08804
http://www.sciencedirect.com/science/article/pii/S2211124716308683
http://www.sciencedirect.com/science/article/pii/S2211124716308683
Autor:
Saroja Ramanujan, Kristin R. Wildsmith, Y. Lu, Y. Zhang, Raymond K. Tong, Jitendra Kanodia, Dennis, Daniela Bumbaca, Sean B. Joseph, Jessica Couch, Ryan J. Watts, Kapil Gadkar, Ernst James, Jasvinder K. Atwal, Kimberly Scearce-Levie, Kwame Hoyte, W. Luk
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology
Anti‐transferrin receptor (TfR)‐based bispecific antibodies have shown promise for boosting antibody uptake in the brain. Nevertheless, there are limited data on the molecular properties, including affinity required for successful development of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f6a1ee8d700472ce1c47033e29ff928
https://doi.org/10.1002/psp4.12081
https://doi.org/10.1002/psp4.12081
Autor:
Y. Joy Yu Zuchero, William H Montgomery, Laura DeForge, William J. Meilandt, Kwame Hoyte, Wilman Luk, Dongping He, Ryan J. Watts, Jasvinder K. Atwal, Kimberly Scearce-Levie, Yanmei Lu
Publikováno v:
Bioanalysis. 8:1067-1075
Aim: Transgenic mice that overexpress human amyloid precursor protein with Swedish or London (APPswe or APPlon) mutations have been widely used for preclinical Alzheimer's disease (AD) drug development. AD patients, however, rarely possess these muta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e831962a6032c53ee761cd7ca8c4bcd6
https://doi.org/10.4155/bio-2016-0003
https://doi.org/10.4155/bio-2016-0003